HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of erythropoietin-dextran microparticle-based PLGA/PLA microspheres on RGCs.

AbstractPURPOSE:
We explored the neuroprotective effects of erythropoietin (EPO)-loaded dextran microparticle-based Poly(DL-lactide-co-glycolide)/Poly(DL-lactide) (PLGA/PLA) microspheres (EPO-dextran PLGA/PLA microspheres) on retinal ganglion cells (RGCs) in optic nerve crush rats for a prolonged period of time.
METHODS:
EPO-dextran PLGA/PLA microspheres were prepared first by a novel solid-in-oil-in-water (S/O/W) technique. Then, the in vitro EPO release profile was assessed. Afterward, the bioactive effect of EPO released from EPO-dextran PLGA/PLA microspheres was explored in vitro on the retinal explants. Lastly, the neuroprotective effects of EPO-dextran PLGA/PLA microspheres on RGCs were evaluated in optic nerve crush rats with TUNEL staining for apoptotic RGCs. The level of glial fibrillary acidic protein (GFAP) expressed in retina was explored by immunohistochemistry staining. Survival RGCs were observed by DiI retrograde labeling using a DiI fluorescent tracer (1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate).
RESULTS:
The results demonstrated that a sustained release of EPO from PLGA/PLA microspheres could last for at least 60 days. EPO released from the microspheres showed as efficaciously neuroregenerative as EPO protein solution on retinal explants (P = 0.2554 for neurite density, P = 0.1004 for neurite length). TUNEL staining revealed that EPO-dextran PLGA/PLA microspheres remarkably reduced RGCs death when compared to the control (untreated) group (P < 0.01 at five days and one week post-crush, P < 0.05 at two weeks post-crush). Increased GFAP expression in retina was reduced greatly in EPO-dextran PLGA/PLA microspheres-administrated rats two weeks post optic nerve crush. DiI retrograde labeling revealed that a single injection of EPO-dextran PLGA/PLA microspheres significantly promoted RGCs survival (P < 0.01 at four and eight weeks post-crush).
CONCLUSIONS:
A single intravitreal injection of EPO-dextran PLGA/PLA microspheres appeared to have a prolonged protective effect on RGCs in optic nerve crush rats. The PLGA/PLA microspheres may be a feasible protein delivery system, such as EPO, to intravitreal injection for retinal degeneration diseases.
AuthorsXianfang Rong, Sixing Yang, Huamao Miao, Tingting Guo, Zhenyu Wang, Wanru Shi, Xiaofen Mo, Weien Yuan, Tuo Jin
JournalInvestigative ophthalmology & visual science (Invest Ophthalmol Vis Sci) Vol. 53 Issue 10 Pg. 6025-34 (Sep 07 2012) ISSN: 1552-5783 [Electronic] United States
PMID22871834 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Biocompatible Materials
  • Delayed-Action Preparations
  • Dextrans
  • Drug Carriers
  • Glial Fibrillary Acidic Protein
  • Erythropoietin
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Polyglycolic Acid
  • Lactic Acid
Topics
  • Animals
  • Apoptosis
  • Biocompatible Materials (pharmacology)
  • Cell Survival (drug effects)
  • Cells, Cultured
  • Delayed-Action Preparations
  • Dextrans (pharmacology)
  • Disease Models, Animal
  • Drug Carriers
  • Drug Compounding
  • Erythropoietin (pharmacology)
  • Glial Fibrillary Acidic Protein (biosynthesis)
  • Immunohistochemistry
  • In Situ Nick-End Labeling
  • Lactic Acid (pharmacology)
  • Male
  • Microspheres
  • Polyglycolic Acid (pharmacology)
  • Polylactic Acid-Polyglycolic Acid Copolymer
  • Rats
  • Rats, Sprague-Dawley
  • Retinal Degeneration (drug therapy, metabolism, pathology)
  • Retinal Ganglion Cells (drug effects, metabolism, pathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: